Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001
Response of children with bronchial asthma to combined therapy with an oral immunostimulating drug and antileukotrienes Source: Eur Respir J 2005; 26: Suppl. 49, 159s Year: 2005
Omalizumab, a novel therapy for severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Single inhaler therapy with budesonide/formoterol in an allergic rat model: a new therapeutic strategy in asthma Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Source: Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018 Year: 2019
IL-2 intravenous application as one of the new ways of immunomodulative therapy of the asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 589s Year: 2002
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Preclinical in vivo assessment of ciclesonide, a novel corticosteroid for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma Source: Eur Respir J 2015; 45: 1273-1282 Year: 2015
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
Desensitization therapy for allergic reactions of antituberculous drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011
Add on therapy of pure theophylline sollution with systemic corticosteroid is more effective for the treatment of asthma attack Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020
Therapeutic options for sarcoidosis: old and new Source: Annual Congress 2005 - PG15 - Therapeutic options for interstitial lung diseases in 2005 Year: 2005